SCHEMBL19989280

SCHEMBL19989280

Cc1cc(S(=O)(=O)N2CCC(O)CC2)ccc1Br

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.55
RIN1 Q13671 1/20 0.55
ALDH1A1 P00352 5/20 0.52
KMT2A Q03164 4/20 0.52
MEN1 O00255 3/20 0.52
LMNA P02545 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
HSD11B1 P28845 1/20 0.51
GAA P10253 2/20 0.50
MCOLN3 Q8TDD5 2/20 0.50
PKM P14618 1/20 0.50
POLB P06746 1/20 0.50
HTT P42858 1/20 0.50
TSHR P16473 2/20 0.49
KDM4E B2RXH2 1/20 0.49
MAPT P10636 2/20 0.48
HSD17B10 Q99714 1/20 0.48
TP53 P04637 1/20 0.48
THRB P10828 1/20 0.48
NPC1 O15118 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29859621 1.00 ABL1 (0.55) ABL1RIN1ALDH1A1KMT2AMEN1
SCHEMBL29859401 0.92 ALDH1A1 (0.50) ABL1RIN1ALDH1A1KMT2AMEN1
SCHEMBL19989346 0.92 ALDH1A1 (0.50) ABL1RIN1ALDH1A1KMT2AMEN1
SCHEMBL19989344 0.92 ALDH1A1 (0.50) ABL1RIN1ALDH1A1KMT2AMEN1
SCHEMBL19989448 0.92 ALDH1A1 (0.50) ABL1RIN1ALDH1A1KMT2AMEN1
SCHEMBL29859224 0.92 ALDH1A1 (0.50) ABL1RIN1ALDH1A1KMT2AMEN1
SCHEMBL19989508 0.85 ALDH1A1 (0.51) ABL1RIN1ALDH1A1KMT2AMEN1
SCHEMBL29859787 0.85 ALDH1A1 (0.51) ABL1RIN1ALDH1A1KMT2AMEN1
SCHEMBL29859274 0.83 ALDH1A1 (0.66) ABL1RIN1ALDH1A1KMT2AMEN1
SCHEMBL17790336 0.83 ALDH1A1 (0.66) ABL1RIN1ALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109715608-B Indazole compounds for use in tendon and/or ligament injuries 诺华股份有限公司 2022-08-05 CN disclosed
EP-3515894-B1 INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES NOVARTIS AG (CH) 2021-04-07 EP disclosed
EP-3515894-A1 INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES Novartis AG (CH) 2019-07-31 EP disclosed
US-10112907-B2 Substituted indazoles for treating tendon and/or ligament injuries NOVARTIS AG (CH) 2018-10-30 US disclosed
US-20180086716-A1 Indazole Compounds for Use in Tendon and/or Ligament Injuries NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION 2018-03-29 US disclosed
WO-2018055550-A1 INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES NOVARTIS AG (CH) 2018-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10112907-B2 Substituted indazoles for treating tendon and/or ligament injuries SLC10A2, MMP1, TNNI3 ABL1 692/4885RIN1 3867/4885ALDH1A1 442/4885
US-20180086716-A1 Indazole Compounds for Use in Tendon and/or Ligament Injuries MMP1, SLC10A2, TNNI3 ABL1 1179/4885RIN1 3481/4885ALDH1A1 414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.